Daniel Abdun-Nabi - Jun 1, 2024 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
Director
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Jun 1, 2024
Transactions value $
$0
Form type
4
Date filed
6/3/2024, 04:58 PM
Previous filing
Aug 10, 2023
Next filing
Jul 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +7 +3.7% 196 Jun 1, 2024 Direct F1, F2
transaction APVO Common Stock Options Exercise +81 +41.33% 277 Jun 2, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -7 -100% $0.00* 0 Jun 1, 2024 Common Stock 7 Direct F1, F3
transaction APVO Restricted Stock Unit Options Exercise $0 -81 -100% $0.00* 0 Jun 2, 2024 Common Stock 81 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On March 5, 2024, the Issuer effected a 1-for-44 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 On June 1, 2021, the reporting person was granted 893 (20 post-split) RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.
F4 On June 2, 2023, the reporting person was granted 3,571 (81 post-split) RSUs, vesting in full on the first anniversary of the date of grant.